<DOC>
	<DOCNO>NCT01904110</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy Safety Monthly ( RisenexM group ) versus Weekly Oral risedronate ( Risenexsplus group ) Korean postmenopausal osteoporotic woman ( Phase IV )</brief_summary>
	<brief_title>To Evaluate Efficacy Safety Monthly Versus Weekly Oral Risedronate With Vitamin D Compliance , Improvement Vitamin D BMD Korean Postmenopausal Osteoporotic Women</brief_title>
	<detailed_description>The purpose study evaluate Efficacy Safety Monthly ( RisenexM group ) versus Weekly Oral risedronate ( Risenexsplus group ) Vitamin D compliance , improvement vitaminD BMD Korean postmenopausal osteoporotic woman ( Phase IV )</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>1 . Female osteoporosis patient 19years age ( menopause ) . Definition osteporosis They BMD Tscore 2.5 less mean Lumbar spine ( L1~L4 ) , Femoral neck total . Or evidence least one vertebral fracture . Definition menopause ( one three condition ) For 12months spontaneous amenorrhea For 6months spontaneous amenorrhea serum FSH ( Follicle stimulate hormone ) 40 mlIU/mL 6weeks bilateral ovariectomy whether hysterectomy 2 . Patients treat oral bisphosphonate drug 3 . Patients adequate measure DXA ( Dual energy xray absorptiometry ) 4 . Patients make voluntary agreement explanation study 5 . Patients participate clinical trial ( HL_RSNP_401 ) must take Risenexplus finish study 12 month . 1 . Patients esophagus disorder . 2 . Patients administered osteoprosis therapy ( except calcium , Vit.D medication ) within previous 3 month 3 . Patients serum calcium concentration 8.0mg/dL . 4 . Patients severe nephropathy ( serum creatinine &gt; doulble normal level 5 . Patients unable sit upright stand 30minutes .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Risedronate , cholecalciferol , BMD , montly , weekly , compliance</keyword>
</DOC>